Skip to content
Menu

Walmart Gets Bullish Rating Despite Pharmacy Deflation Headwinds

Lekha Gupta 11 hours ago

MoversNewsAnalyst RatingsAnalyst ColorEarningsGuidanceTop StoriesEquities

BTIG expects Walmart's underlying demand to remain healthy while Maximum Fair Price pharmacy deflation continues weighing on reported comparable sales.

Walmart Inc. (NASDAQ:WMT) shares are recovering on Friday after declining on Thursday following its third-quarter results.

It reported an adjusted EPS of 65 cents, exceeding analyst expectations of 64 cents. The figure excludes an after-tax loss of 3 cents per share related to equity and other investments.

Revenue rose 5.2% year over year to $188.835 billion, topping the consensus estimate of $187.271 billion.

However, Walmart’s weight-loss drug windfall is losing momentum despite rising prescription volumes.

Analyst Price Forecast Revisions

Several analysts raised their price forecasts following Walmart’s third-quarter results and increased guidance, while maintaining their existing ratings.

  • Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and raised his price forecast to $135 from $125.
  • Piper Sandler analyst Peter Keith maintained an Overweight rating and increased his price forecast to $138 from $128.
  • TD Cowen analyst Max Rakhlenko maintained a Buy rating and raised his price forecast to $147 from $125.
  • Truist Securities analyst Scot Ciccarelli maintained a Buy rating and increased his price forecast to $134 from $114.
  • BTIG analyst Robert Drbul reiterated a Buy rating and maintained his $140 price forecast.

BTIG Analyst View

Drbul believes Walmart’s underlying U.S. business remains healthy, although Health & Wellness (H&W) is expected to weigh on reported comparable sales.

Walmart’s 2.9% U.S. comparable sales growth included an approximately 125-basis-point drag from Maximum Fair Price-related pharmacy deflation and brand-to-generic transfers, partly offset by a roughly 60-basis-point contribution from GLP-1 drugs.

Excluding H&W, comparable sales increased 3.6%, slightly accelerating from the second quarter of fiscal 2027 and improving on a two-year basis.

Looking ahead, the analyst expects healthy underlying demand but anticipates continued pressure on reported comparable sales from H&W.

MFP-related headwinds are expected to remain near current levels or increase slightly, while the contribution from GLP-1 drugs is likely to moderate.

However, improving H&W gross profit margins should help cushion the impact of weaker reported sales, according to the analyst.

Earnings Estimates And Outlook

Drbul maintained his fiscal 2027 EPS estimate at $2.90 but lowered his fourth-quarter Walmart U.S. comparable sales growth forecast to 2.9% from 3.1%. He expects comparable sales to increase 3.6% excluding H&W.

The analyst expects fiscal 2027 net sales of $748 billion, representing approximately 6% year-over-year growth, with operating income projected to grow faster than sales.

For fiscal 2028, Drbul raised his EPS estimate to $3.25 from $3.15.

WMT Price Action: Walmart shares were up 2.82% at $129.60 at the time of publication on Friday, according to Benzinga Pro data.

Photo via Shutterstock 

Read at benzinga.com

← All stock news